NCT03113500 - Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

July 16, 2021

Study Completion Date

August 12, 2025

Conditions

Adult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveAngioimmunoblastic T-Cell LymphomaAnn Arbor Stage II Noncutaneous Anaplastic Large Cell LymphomaAnn Arbor Stage III Noncutaneous Anaplastic Large Cell LymphomaAnn Arbor Stage IV Noncutaneous Anaplastic Large Cell LymphomaEnteropathy-Associated T-Cell LymphomaHepatosplenic T-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions

DRUG

Brentuximab Vedotin

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Etoposide

Given IV

DRUG

Etoposide Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Prednisone

Given PO

Trial Locations (5)

43210

Ohio State University Comprehensive Cancer Center, Columbus

77030

M D Anderson Cancer Center, Houston

91010

City of Hope Comprehensive Cancer Center, Duarte

07601

Hackensack University Medical Center, Hackensack

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER